MetaVia to Hold Advisory Committee Meeting at the 9th Annual MASH-TAG 2025 Conference

Rhea-AI Summary

MetaVia (NASDAQ: MTVA) announced it will hold an Advisory Committee meeting at the 9th Annual MASH-TAG 2025 Conference to discuss previously announced positive top-line 16-week results from their Phase 2a clinical trial. The trial evaluated DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH).

The conference is being held from January 9-11 at the Chateaux Deer Valley in Park City, Utah. MetaVia's management and clinical team will be available in the Exhibit Hall to discuss the trial results, and the presentation will be accessible on the company's website.

News Market Reaction – MTVA

-3.29%

-3.29% Session move

In the trading session that priced this news, MTVA declined 3.29%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., Jan. 10, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it is holding an Advisory Committee meeting today, at the 9^th Annual MASH-TAG 2025 Conference, to discuss the previously announced positive top-line 16-week results from the two-part Phase 2a clinical trial of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH). The MASH-TAG Conference is taking place January 9-11 at the Chateaux Deer Valley in Park City, Utah. Members of MetaVia's management and clinical team will be available in the Exhibit Hall at the Conference to discuss the results of the Phase 2a clinical trial of DA-1241.

A copy of the presentation will be available on the Events and Presentations section of the MetaVia website.

About MetaVia
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control.

For more information, please visit www.metaviatx.com.

Contacts:

MetaVia
Marshall H. Woodworth
Chief Financial Officer
+1-857-299-1033
marshall.woodworth@metaviatx.com

Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/metavia-to-hold-advisory-committee-meeting-at-the-9th-annual-mash-tag-2025-conference-302347510.html

SOURCE MetaVia Inc.

FAQ

What are the Phase 2a trial results for MetaVia's DA-1241 (MTVA) being discussed at MASH-TAG 2025?

MetaVia is discussing the positive top-line 16-week results from their Phase 2a clinical trial of DA-1241, a GPR119 agonist, in patients with presumed MASH at the MASH-TAG 2025 Conference.

When and where is MetaVia (MTVA) presenting at the MASH-TAG 2025 Conference?

MetaVia is presenting on January 10, 2025, at the MASH-TAG Conference, taking place January 9-11 at the Chateaux Deer Valley in Park City, Utah.

How can investors access MetaVia's (MTVA) MASH-TAG 2025 presentation materials?

The presentation will be available on the Events and Presentations section of MetaVia's website.

What is the therapeutic target of MetaVia's (MTVA) DA-1241 drug candidate?

DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH).